Waxman Opposes Hatch Plan To Keep Generics Out Of PTAB

Law360 (October 30, 2018, 7:22 PM EDT) -- A proposal by one of the architects of the Hatch-Waxman Act to effectively bar generic-drug makers from challenging patents at the Patent Trial and Appeal Board has met opposition from the bill's other named sponsor, who said he will be "vigorously opposing" the idea.

Former Rep. Henry Waxman, D-Calif., said in a podcast interview with Eli Mazour of Harrity & Harrity LLP released Monday that he is "strongly against" the Hatch-Waxman Integrity Act, a bill that his co-namesake, Sen. Orrin Hatch, R-Utah, proposed in June.

The legislation, which has not yet been introduced, would require companies filing abbreviated new drug applications...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS